Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Novo Nordisk
Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
An Open-label, Multi-centre, Un-controlled Trial to Assess Efficacy and Safety of NNC-0156-0000-0009 during Surgical Procedures in Patients with Haemophilia B
To evaluate the haemostatic effect of NNC-0156-0000-0009 during surgery procedures in patients with haemophilia B
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
LEADER Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results A Long-term, Multi-centre, International, Randomised Double-blind, Placebo-controlled Trial to Determine Liraglutide Effects on Cardiovascular Events
To assess the effect of treatment with liraglutide compared to placebo for at least 3.5 year and up to 5 years on the incidence of cardiovascular events, as defined by the below primary and secondary ...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
A trial comparing efficacy and safety of NN1250 and insulin glargine in subjects with type 2 diabetes
To confirm the efficacy of SIBA 200 U/ml once daily + metformin ± DPP-4 inhibitor in controlling glycaemia with respect to change from baseline in HbA_1c after 26 weeks of treatment. This is done by c...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
A trial investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of long-acting growth hormone compared to daily dosing of Norditropin® SimpleXx® in children with growth hormone deficiency
To evaluate safety and tolerability of a single subcutaneous (s.c.) dose of NNC0195-0092 compared to daily dosing of Norditropin® SimpleXx® for seven days in children with growth hormone deficiency (G...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
A Multi-Centre, Randomised, Double-Blind, Placebo Controlled Trial on Efficacy and Safety of FXIII Replenishment with two different Doses of Recombinant Factor XIII following Cardiopulmonary Bypass Surgery
To investigate whether postoperative treatment with either of two doses (17.5 or 35 IU/kg LBM) of recombinant factor FXIII (rFXIII) is effective in avoiding any allogeneic transfusions in cardio pulmo...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
A trial comparing the efficacy and safety of insulin degludec/liraglutide versus insulin glargine in subjects with type 2 diabetes mellitus
To confirm the efficacy of insulin degludec/liraglutide in controlling glycaemia in subjects with type 2 diabetes mellitus (T2DM) on previous treatment with insulin glargine. This is done by compa...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
Comparison of the efficacy and safety of two different dose adjustment regimens for insulin degludec/insulin aspart in subjects with type 2 diabetes mellitus previously treated with insulin glargine
To confirm the efficacy of the insulin degludec/insulin aspart (IDegAsp) twice daily (BID) simple titration algorithm in controlling glycaemia with respect to change from baseline in glycosylated haem...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
The effect of liraglutide versus placebo when added to basal insulin analogues with or without metformin in subjects with type 2 diabetes
To confirm superiority on glycaemic control of liraglutide versus liraglutide placebo after 26 weeks of treatment when added to pre-existing basal insulin analogue treatment (with or without concomita...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
A Randomised, Double-Blind, Placebo-Controlled, Multi-centre, Dose Escalation Study to Evaluate the Safety and Preliminary Efficacy of Recombinant Factor VIIa (NovoSeven®/Niastase®) with Brain Contusions
To evaluate the safety of NovoSeven® in subjects with brain contusions.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Novo Nordisk A/S
MAJ Il y a 4 ans
Effect of liraglutide for weight management in pubertal adolescent subjects with obesity
To compare the efficacy of liraglutide versus placebo on weight loss in adolescent subjects with obesity after 56 weeks of treatment
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
9
10
11
12
13
14
15
16
17
18
Suivant